A Tabula Rasa for pharmacy consulting

SF 383 prohibits PBMs from limiting patient choice of pharmacy, unfairly excluding pharmacies from networks, and forces them to reimburse pharmacies no less than what they pay affiliated pharmacies for the same drug.

Dae Lee, PharmD, Esq, CPBS and Lucas Morgan, Esq, discuss PBM and board of pharmacy enforcement actions, trends in PBM audits, and more.

The new approval is for a first-in-class TRPM8 receptor agonist to stimulate corneal sensory nerves to increase natural tear production.

As artificial intelligence evolves from a novel technology to commonplace in health care, the pharmacy industry is adapting to its challenges and opportunities.

Michael Hegener, PharmD, BCACP, discusses how workforce development can best address the evolving knowledge, skills, and abilities needed in community pharmacy practice.

This designation follows Hadlima’s low-concentration prefilled syringes and single-dose vials, which were designated in June 2024.